|
1）Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol. 2003; 7: 255-9
|
|
|
|
2）Asanuma K, Yanagida-Asanuma E, Takagi M, et al. The role of podocytes in proteinuria. Nephrology(Carlton). 2007; 12 Suppl 3: S15-20
|
|
|
|
|
|
3）Asanuma K, Tomino Y. Regulation of actin cytoskeleton in renal podocytes. Nihon Jinzo Gakkai Shi. 2008; 50: 532-9
|
|
|
|
|
|
4）Asanuma K, Hidaka T, Tomino Y. The cutting-edge of medicine; the role of podocytes in renal diseases. Nihon Naika Gakkai Zasshi. 2012; 101: 1092-101
|
|
|
|
|
5）Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int. 1998; 54: 687-97
|
|
|
|
|
|
6）Jefferson JA, Alpers CE, Shankland SJ. Podocyte biology for the bedside. Am J Kidney Dis. 2011; 58: 835-45
|
|
|
|
|
|
7）Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron. 2001; 89: 342-7
|
|
|
|
|
|
8）Hara M, Yanagihara T, Takada T, et al. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol. 1998; 18: 35-41
|
|
|
|
|
|
9）Asao R, Asanuma K, Kodama F, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 2012; 7: 1385-93
|
|
|
|
|
|
10）Camici M. Urinary detection of podocyte injury. Biomed Pharmacother. 2007; 61: 245-9
|
|
|
|
|
|
11）Asanuma K, Campbell KN, Kim K, et al. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc Natl Acad Sci U S A. 2007; 104: 10134-9
|
|
|
|
|
|
12）Asanuma K, Akiba-Takagi M, Kodama F, et al. Dendrin location in podocytes is associated with disease progression in animal and human glomerulopathy. Am J Nephrol. 2011; 33: 537-49
|
|
|
|
|
|
13）Kodama F, Asanuma K, Takagi M, et al. Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy. Nephrol Dial Transplant. 2012; 28: 1762-72
|
|
|
|
|
|
14）Hara M, Yanagihara T, Kihara I, et al. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol. 2005; 16: 408-16
|
|
|
|
|
|
15）Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009; 20: 1669-76
|
|
|
|
|
|
16）Hara M, Yanagihara T, Hirayama Y, et al. Podocyte membrane vesicles in urine originate from tip vesiculation of podocyte microvilli. Hum Pathol. 2010; 41: 1265-75
|
|
|
|
|
|
17）Kanno K, Kawachi H, Uchida Y, et al. Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract. 2003; 95: c91-9
|
|
|
|
|
|
18）Hara M, Yamagata K, Tomino Y, et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 2012; 55: 2913-9
|
|
|
|
|
|
19）Rood IM, Deegens JK, Merchant ML, et al. Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. Kidney Int. 2010; 78: 810-6
|
|
|
|
|
|
20）Kalani A, Mohan A, Godbole MM, et al. Wilm's tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria. PLoS One. 2013; 8: e60177
|
|
|
|
|
|
21）Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004; 101: 13368-73
|
|
|
|
|
|
22）Prunotto M, Farina A, Lane L, et al. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteomics. 2013; 82: 193-229
|
|
|
|
|
|
23）Sato Y, Wharram BL, Lee SK, et al. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol. 2009; 20: 1041-52
|
|
|
|
|
|
24）Fukuda A, Wickman LT, Venkatareddy MP, et al. Urine podocin: nephrin mRNA ratio(PNR)as a podocyte stress biomarker. Nephrol Dial Transplant. 2012; 27: 4079-87
|
|
|
|
|
|
25）Kubo K, Miyagawa K, Yamamoto R, et al. Detection of WT1 mRNA in urine from patients with kidney diseases. Eur J Clin Invest. 1999; 29: 824-6
|
|
|
|
|
|
26）Wang G, Lai FM, Tam LS, et al. Messenger RNA expression of podocyte-associated molecules in urinary sediment of patients with lupus nephritis. J Rheumatol. 2007; 34: 2358-64
|
|
|
|
|
|
27）Wang G, Lai FM, Lai KB, et al. Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss. Ren Fail. 2010; 32: 372-9
|
|
|
|
|
|
28）Zheng M, Lv LL, Ni J, et al. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One. 2011; 6: e20431
|
|
|
|
|
|
29）Garin EH, Diaz LN, Mu W, et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol. 2009; 20: 260-6
|
|
|
|
|
|
30）Garin EH, Mu W, Arthur JM, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int. 2010; 78: 296-302
|
|
|
|
|
|
31）Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17: 952-60
|
|
|
|
|
|
32）Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012; 23: 2051-9
|
|
|
|
|
|
33）Barraclough R. Calcium-binding protein S100A4 in health and disease. Biochim Biophys Acta. 1998; 1448: 190-9
|
|
|
|
|
|
34）Okada H, Danoff TM, Kalluri R, et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol. 1997; 273(4 Pt 2): F563-74
|
|
|
|
|
|
35）Samejima K, Nakatani K, Suzuki D, et al. Clinical significance of fibroblast-specific protein-1 expression on podocytes in patients with focal segmental glomerulosclerosis. Nephron Clin Pract. 2012; 120: c1-7
|
|
|
|
|
|
36）Yamaguchi Y, Iwano M, Suzuki D, et al. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis. 2009; 54: 653-64
|
|
|
|
|
|
37）Iwano M, Yamaguchi Y, Iwamoto T, et al. Urinary FSP1 is a biomarker of crescentic GN. J Am Soc Nephrol. 2012; 23: 209-14
|
|
|
|
|